Genetic variants predict recurrence of bladder cancer, patient survival
Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy. Patients with risk-reducing genotypes were 84 percent less likely to have their disease recur after treatment with Bacillus Calmette-Guerin (BCG), the prevailing immunotherapy to prevent high-risk NMIBC patients from developing recurrence. The recurrence-free median survival time among these patients was 96.7 months compared with 47 months among those with the more typical genotype, the team reported at the 100th Annual Meeting of the American Association for Cancer Research.
"The future purpose of this kind of study is personalized cancer therapy," said senior author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology at M. D. Anderson. "This genetic information is an essential step toward constructing a blueprint that will determine treatment response and follow-up strategy."
Currently, the primary treatment for NMIBC is transurethral resection - surgical removal of the tumor tissues from bladder - combined with chemotherapy or immunotherapy such as BCG injection. Overall, the recurrence rate is around 50 percent over four years.
In this study of 596 patients at M. D. Anderson, 46 percent of those who had a common genotype of the inducible nitric oxide synthase (iNOS) gene experienced a recurrence after receiving maintenance BCG therapy. Only 22 percent of patients with the variant-containing genotypes had a recurrence with the same treatment. The results suggest that BCG may be more effective when administered to individuals with genotypes containing the variant allele of the iNOS gene.
"We aimed to determine why some patients respond to BCG and others don't," said lead author Hushan Yang, Ph.D., a postdoctoral fellow in the Department of Epidemiology at M. D. Anderson.
Yang and his colleagues evaluated 59 single nucleotide polymorphisms (SNPs) in 35 major inflammation genes. Using a combined analysis, they stratified patients into multiple risk groups. Those patients in the high-risk group were found to have a median survival time of only 13.5 months, while those in the low-risk group were recurrence free for more than 96.7 months.
"Once validated, the next step will be to create a risk prediction model," said Wu. "Combining the information we have with other aspects such as clinical, epidemiological and behavioral variables, as well as tumor characteristics, patient characteristics and other genetic information will allow treating physicians to know whether their patient is likely to respond to therapy or experience a recurrence."
- Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancerWed, 9 Dec 2009, 11:15:10 EST
- Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patientsMon, 7 Dec 2009, 14:37:08 EST
- Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study findsWed, 3 Mar 2010, 18:44:59 EST
- More intense bladder cancer treatment does not improve survival, U-M study findsTue, 7 Apr 2009, 16:50:27 EDT
- Genetic variation cuts bladder cancer risk, protects chromosome tipsSat, 2 Apr 2011, 17:33:14 EDT
Articles on the same topic
- Genetic analysis may predict risk of invasive bladder cancerMon, 20 Apr 2009, 14:50:38 EDT
- Genetic variants predict recurrence of bladder cancer, patient survivalMon, 20 Apr 2009, 14:50:37 EDT
- Genetic variations in miRNA processing pathway and binding sites help predict ovarian cancer riskSun, 19 Apr 2009, 15:50:25 EDT
- Genetic Variants Predict Recurrence Of Bladder Cancer, Patient Survivalfrom Science DailyThu, 23 Apr 2009, 11:29:18 EDT
- Genetic variants predict recurrence of bladder cancer, patient survivalfrom Science CentricTue, 21 Apr 2009, 7:49:38 EDT
- Genetic analysis may predict risk of invasive bladder cancerfrom Science CentricTue, 21 Apr 2009, 7:49:16 EDT
- Genetic variants predict recurrence of bladder cancer, patient survivalfrom Science BlogMon, 20 Apr 2009, 15:49:12 EDT
- Genetic variants predict recurrence of bladder cancer, patient survivalfrom PhysorgMon, 20 Apr 2009, 14:49:10 EDT
- Genetic Variations In MiRNA Processing Pathway And Binding Sites Help Predict Ovarian Cancer Riskfrom Science DailySun, 19 Apr 2009, 18:07:14 EDT
- Genetic variations in miRNA processing pathway and binding sites help predict ovarian cancer riskfrom PhysorgSun, 19 Apr 2009, 15:49:18 EDT